Eric Ostertag - 01 Feb 2022 Form 4 Insider Report for Poseida Therapeutics, Inc.

Role: Executive Chairman, Director, 10%+ Owner
Signature: /s/ Harry J. Leonhardt, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 01 Feb 2022, 20:48:11 UTC
Previous filing: 22 Nov 2021
Next filing: 05 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	Common Stock	Gift	$0	-93,955	-13%	$0.000000	603,467	30 Dec 2021	Direct
transaction	PSTX	Common Stock	Gift	$0	-48,902	-7.8%	$0.000000	580,292	30 Dec 2021	See footnote	F1
transaction	PSTX	Common Stock	Award	$0	+89,500	+15%	$0.000000	692,967	01 Feb 2022	Direct	F2
holding	PSTX	Common Stock						3,659,503	01 Feb 2022	See footnote	F3
holding	PSTX	Common Stock						3,358,455	01 Feb 2022	See footnote	F4
holding	PSTX	Common Stock						961,445	01 Feb 2022	See footnote	F5
holding	PSTX	Common Stock						160,696	01 Feb 2022	See footnote	F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PSTX	Employee Stock Option (Right to Buy)	Award	$0	+118,708		$0.000000	118,708	01 Feb 2022	Common Stock	118,708	$4.75	Direct	F7
transaction	PSTX	Employee Stock Option (Right to Buy)	Award	$0	+10,792		$0.000000	10,792	01 Feb 2022	Common Stock	10,792	$5.23	Direct	F7, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
F2	Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in two equal annual installments.
F3	The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
F4	The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F5	The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.
F6	The shares are held in the name of Transposagen Biopharmaceuticals, Inc., of which Dr. Ostertag is a majority stockholder.
F7	25% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 18 equal monthly installments thereafter.
F8	The exercise price of the incentive stock option is equal to 110% of the fair market value of the Issuer's common stock on the date of grant, due to the reporting person's status as the beneficial owner of 10% or more of the Issuer's common stock on the grant date.